Impact of resistance training on older patients with diabetes and muscle loss
Evaluating Resistance Training for Sarcopenia in Older Patients With Type 2 Diabetes: Treatment Outcomes
This study tests if a 12-week program of resistance training can help older people with type 2 diabetes and muscle loss improve their muscle strength and function.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 60 Years to 80 Years |
| Sex | All |
| Sponsor | National Geriatric Hospital Government |
| Locations | 1 site (Hanoi) |
| Trial ID | NCT06337357 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effects of progressive resistance training on older patients with type 2 diabetes who have been diagnosed with sarcopenia. The intervention consists of 12 weeks of resistance exercises, with approximately 24 sessions planned. Outcome measures will be assessed at baseline, and at 4, 8, and 12 weeks to evaluate improvements in muscle mass and function. The study aims to provide insights into non-pharmacological interventions for managing sarcopenia in this population.
Who should consider this trial
Good fit: Ideal candidates are older adults aged 60 to 80 with type 2 diabetes and diagnosed sarcopenia.
Not a fit: Patients with acute diabetic complications or significant cognitive and mobility impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance muscle strength and overall health in older patients with diabetes, potentially reducing the risk of falls and improving quality of life.
How similar studies have performed: Previous studies have shown positive outcomes with resistance training in older adults, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Type 2 diabetic patients diagnosed using American Diabetes Association 2022 criteria * HbA1c ≥ 7.0 and ≤ 8.5% * Sarcopenia diagnosed using criteria from the Asian Working Group for Sarcopenia 2019 * Age ≥ 60 and ≤ 80 Exclusion Criteria: * Acute diabetic complications * Patients are in the acute phase of musculoskeletal disorders: acute gout, progressing low-grade arthritis, acute joint pain due to joint degeneration, sciatic pain, and infectious arthritis. * Patients suffer from conditions significantly affecting cognition and mobility: sequelae of stroke (with weakness, limb paralysis), muscular weakness, limb disabilities, severe heart failure, severe cognitive decline, and psychiatric disorders. * Patients have been bedridden due to illness for more than 1 month within the past 3 months up to the recruitment time. * Patients with cardiovascular diseases: chest pain, uncontrolled blood pressure ≥160/100 mmHg, untreated cardiac arrhythmia, a history of congestive heart failure, severe valvular heart disease, myocarditis or pericarditis, and hypertrophic cardiomyopathy. * Renal failure with estimated glomerular function rate (Modification of Diet in Renal Disease equation) \< 60 ml/min/m3 or serum creatinine ≥ 130 µmol/l * On treatment with Sodium-glucose cotransporter 2 inhibitors (SGLT2i)
Where this trial is running
Hanoi
- National Geriatric Hospital — Hanoi, Vietnam (Recruiting)
Study contacts
- Study coordinator: Anh N Trinh, MD
- Email: drtrinhanh.endo@gmail.com
- Phone: (+84) 912760684
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.